公开(公告)号：US20110286934A1

公开(公告)日：2011-11-24

申请号：US13129942

申请日：2009-10-07

Applicant: Walter Kisiel

Inventor： Walter Kisiel

IPC: A61K49/00 ,  C07K7/08 ,  C07K14/47 ,  C07K19/00 ,  C07H21/00 ,  C12N5/07 ,  C12N15/87 ,  C12Q1/02 ,  A61K9/127 ,  A61K38/02 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17 ,  A61K38/14 ,  A61P35/00 ,  C07K7/06

CPC classification number: C07K14/8114 ,  A61K38/00 ,  A61K47/64

Abstract: Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition.

Abstract translation: 本文描述了与材料的细胞内化相关的分离的多肽，核酸和方法。 通常，分离的多肽包括人组织因子途径抑制剂-2（TFPI-2）的膜转导结构域。 在一些情况下，分离的多肽可以是包含人TFPI-2的膜转导结构域和异源肽结构域的融合肽。 核酸包括编码本文所述分离的多肽的核酸。 所述方法通常包括提供包含与材料偶联的人TFPI-2的膜转导结构域的组合物，以及在有效地允许细胞内化组合物的条件下使组合物与细胞接触。

公开(公告)号：US07961975B2

公开(公告)日：2011-06-14

申请号：US11831353

申请日：2007-07-31

Applicant: Ousseini Lankoande ,  Majeed Hayat ,  Balu Santhanam

Inventor： Ousseini Lankoande ,  Majeed Hayat ,  Balu Santhanam

IPC: G06K9/40

CPC classification number: G06K9/0063 ,  G06K9/40 ,  G06K9/4638 ,  G06T5/002 ,  G06T2207/10132 ,  G06T2207/20012

Abstract: The present invention includes methods for the reduction of speckle noise in an image and methods for segmenting an image. Each of the methods disclosed herein includes steps for analyzing the uniformity of a pixel within a plurality of pixels forming a portion of the image and, based on the uniformity of the intensity of the plurality of pixels, adjusting and/or replacing the pixel in order to produce a speckle-noise reduced image, a segmented image, or a segmented and speckle-noise reduced image. The methods of the present invention can employ for example conditional probability density functions, nonlinear estimator functions, convex energy functions and simulated annealing algorithms in the performance of their respective steps.

Abstract translation: 本发明包括用于减少图像中的斑点噪声的方法和用于分割图像的方法。 本文公开的每种方法包括用于分析形成图像的一部分的多个像素内的像素的均匀性的步骤，并且基于多个像素的强度的均匀性，按顺序调整和/或替换像素 以产生斑点噪声缩小图像，分割图像或分割和斑点噪声缩小图像。 本发明的方法可以在其各自的步骤的执行中使用例如条件概率密度函数，非线性估计函数，凸能量函数和模拟退火算法。

公开(公告)号：US07728115B2

公开(公告)日：2010-06-01

申请号：US11195095

申请日：2005-08-02

Applicant: Gowthami M. Arepally ,  Walter Kisiel ,  Keiko Kamei ,  Shintaro Kamei

Inventor： Gowthami M. Arepally ,  Walter Kisiel ,  Keiko Kamei ,  Shintaro Kamei

IPC: C07K16/18 ,  C12P21/08 ,  G01N33/564 ,  G01N33/577 ,  C12N5/20

CPC classification number: C07K16/24 ,  C07K16/18 ,  C07K2317/32 ,  C07K2317/75 ,  G01N33/86 ,  G01N2333/96463 ,  G01N2400/40 ,  Y10S435/975 ,  Y10S530/866

Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.

Abstract translation: 本发明包括组合物，试剂盒和方法，其包含与哺乳动物参与肝素诱导的血小板减少症/血栓形成（HIT / HITT）发病机理的多克隆抗体共享关键功能特性的单克隆抗体。 本发明的单克隆抗体相对于抗体与单独的PF4或肝素的结合优先与PF4 /肝素复合物结合。 本发明的单克隆抗体也与除了肝素之外的其它糖胺聚糖的复合物中的PF4特异性结合，并且还激活血小板。 本发明的单克隆抗体可用于哺乳动物诊断和治疗HIT / HITT的方法。 还包括本发明的单克隆抗体的人源化版本，以及本发明的单克隆抗体的人源化方法。

公开(公告)号：US20100008390A1

公开(公告)日：2010-01-14

申请号：US12387714

申请日：2009-05-06

Applicant: Marek A. Osinski ,  Omar K. Qassim ,  Nathan J. Withers ,  Gennady A. Smolyakov

Inventor： Marek A. Osinski ,  Omar K. Qassim ,  Nathan J. Withers ,  Gennady A. Smolyakov

IPC: H01S5/34 ,  H01S5/026 ,  H01S5/12

CPC classification number: H01S5/125 ,  B82Y20/00 ,  H01S5/0064 ,  H01S5/026 ,  H01S5/0683 ,  H01S5/1025 ,  H01S5/1032 ,  H01S5/1071 ,  H01S5/1085 ,  H01S5/2213 ,  H01S5/227 ,  H01S5/34306 ,  H01S5/4006

Abstract: A unidirectional semiconductor ring laser (USRL) section is monolithically integrated with a DFB or DBR master laser section on a semiconductor substrate of a light-emitting device to provide an injection locking mode of operation that can result in low-cost ultrafast (over 100 GHz) functional chip that will be easy to use in practice.

Abstract translation: 单向半导体环形激光器（USRL）部分与发光器件的半导体衬底上的DFB或DBR主激光器部分单片集成，以提供可以导致低成本超快（超过100GHz）的注入锁定模式 ）功能芯片，在实践中将易于使用。

公开(公告)号：US20090208493A1

公开(公告)日：2009-08-20

申请号：US12315132

申请日：2008-11-28

Applicant: Richard S. Larson ,  Larry A. Sklar ,  Bruce S. Edwards ,  Irena D. Ivnitski-Steele ,  Tudor I. Oprea ,  Debbie M. Lovato ,  Hadya M. Khawaja ,  Stuart S. Winter ,  Susan M. Young

Inventor： Richard S. Larson ,  Larry A. Sklar ,  Bruce S. Edwards ,  Irena D. Ivnitski-Steele ,  Tudor I. Oprea ,  Debbie M. Lovato ,  Hadya M. Khawaja ,  Stuart S. Winter ,  Susan M. Young

IPC: A61K38/13 ,  A61K33/24 ,  A61K39/395 ,  A61K31/57 ,  G01N33/50 ,  A61P35/00

CPC classification number: A61K31/12 ,  A61K31/415 ,  A61K45/06 ,  A61K2300/00

Abstract: Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed.

Abstract translation: 公开的抑制ABCB1转运蛋白的化合物可用于治疗其中ABCB1转运蛋白介导疾病状态的疾病，包括许多癌症，包括造血癌，包括各种白血病，特别是T-lineage急性成淋巴细胞白血病，以及癌性肿瘤，特别是形式 其表现出多种耐药性。 包含ABCB1转运蛋白抑制剂和至少一种另外的抗癌剂的药物组合物，任选与药学上可接受的载体，添加剂或赋形剂组合是本发明的另一方面。 还公开了量化ABCB1流出的基于流式细胞术的高通量筛选（HST）测定。 还公开了鉴定ABCB1，ABCG2和ABCC1转运蛋白抑制剂的方法。

公开(公告)号：US07314760B2

公开(公告)日：2008-01-01

申请号：US10862791

申请日：2004-06-07

Applicant: Laurence A Cole ,  Jaime M Riley

Inventor： Laurence A Cole ,  Jaime M Riley

IPC: G01N33/48 ,  G01N33/50 ,  A61K38/24

CPC classification number: G01N33/76 ,  G01N2333/59

Abstract: The invention provides prenatal screening methods for Down's syndrome. Specifically, the methods of the invention comprise determining the amount of hyperglycosylated human chorionic gonadotropin (hCG) charge isoforms in a biological sample from a pregnant woman and comparing the amount of highly acidic and less acidic isoforms with those found in a sample taken from a pregnant woman carrying a normal fetus. The methods of the invention can be employed during any stage of pregnancy.

Abstract translation: 本发明提供唐氏综合征的产前筛查方法。 具体地说，本发明的方法包括确定来自孕妇的生物样品中高糖基化的人绒毛膜促性腺激素（hCG）电荷同种型的量，并将高度酸性和酸性较弱的同种型的量与从怀孕 携带正常胎儿的女人 本发明的方法可以在怀孕的任何阶段中使用。

公开(公告)号：US07282732B2

公开(公告)日：2007-10-16

申请号：US10971555

申请日：2004-10-21

Applicant: Allen L Gray ,  Andreas Stintz ,  Kevin J Malloy ,  Luke F Lester ,  Petros M Varangis

Inventor： Allen L Gray ,  Andreas Stintz ,  Kevin J Malloy ,  Luke F Lester ,  Petros M Varangis

IPC: H01L29/06

CPC classification number: B82Y10/00 ,  B82Y20/00 ,  H01L21/02392 ,  H01L21/02433 ,  H01L21/02463 ,  H01L21/02505 ,  H01L21/02513 ,  H01L21/02546 ,  H01S5/2201 ,  H01S5/3412 ,  H01S5/34366 ,  H01S2304/02

Abstract: Symmetric quantum dots are embedded in quantum wells. The symmetry is achieved by using slightly off-axis substrates and/or overpressure during the quantum dot growth. The quantum dot structure can be used in a variety of applications, including semiconductor lasers.

Abstract translation: 对称量子点嵌入在量子阱中。 通过在量子点生长期间使用稍微离轴的衬底和/或超压实现对称性。 量子点结构可用于各种应用，包括半导体激光器。

公开(公告)号：US20240261378A1

公开(公告)日：2024-08-08

申请号：US16321699

申请日：2017-07-31

Applicant: STC UNM

Inventor： Vojo Deretic

IPC: A61K38/53 ,  A61K31/05 ,  A61K31/137 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/616 ,  A61K31/7016 ,  A61K31/702 ,  A61K38/17 ,  A61K45/06 ,  A61P31/04

CPC classification number: A61K38/53 ,  A61K31/05 ,  A61K31/137 ,  A61K31/155 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/616 ,  A61K31/7016 ,  A61K31/702 ,  A61K38/1732 ,  A61K45/06 ,  A61P31/04

Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRIM 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence autophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.

公开(公告)号：US20220183945A1

公开(公告)日：2022-06-16

申请号：US17438362

申请日：2020-03-10

Applicant: STC. UNM

Inventor： Dominique Renee Perez ,  Larry A. Sklar ,  Alexandre Chigaev ,  Alison F. Franks

IPC: A61K8/49 ,  A61Q19/00 ,  A61Q15/00

Abstract: The present invention is directed to previously identified inhibitors of cAMP efflux (ICE) and their use in treating/masking body odor, inhibiting, reducing and/or eliminating hyperhidrosis (excessive sweating), tanning skin or protecting skin before and/or after exposure to the sun as well as for treating certain skin conditions, in one embodiment, the invention provides a method for inhibiting body odor, a condition that is characterized by an unpleasant odor from the products of the microbial sweat degradation. By inhibiting the efflux of the precursor compounds that are degraded, novel compounds are capable of preventing unwanted odors. Deodorant compositions that employ this new approach for the control of bodily odor are provided, ICE compounds can also be used as components, of cosmetic formulations including tanning and after-sun formulations, formulations for skin conditions as described herein and other cosmetic formulation.

公开(公告)号：US20210079474A1

公开(公告)日：2021-03-18

申请号：US17050285

申请日：2019-04-25

Applicant: STC. UNM

Inventor： Nikolaos MELLIOS

IPC: C12Q1/6883

Abstract: A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and/or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit/Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.